US OptionsDetailed Quotes
MNOV241115P2500
- 0.50
- -0.30-37.50%
15min DelayClose Nov 12 16:00 ET
0.60High0.50Low
0.60Open0.80Pre Close14 Volume21 Open Interest2.50Strike Price807.00Turnover454.30%IV12.28%PremiumNov 15, 2024Expiry Date0.22Intrinsic Value100Multiplier3DDays to Expiry0.28Extrinsic Value100Contract SizeAmericanOptions Type-0.5109Delta0.4351Gamma4.56Leverage Ratio-0.0704Theta-0.0001Rho-2.33Eff Leverage0.0008Vega
MediciNova Stock Discussion
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova (NASDAQ: MNOV) announced it will receive monetary damages following the settlement of Sanofi-Novartis litigation. The company plans to use this non-dilutive fundingto support ongoing clinical development programs, particularly focusing on their late-stage pipeline targeting inflammatory, metabolic, and neurodegenerative diseases. The settlement validates MediciNova's in...
Medicinova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
MediciNova (NASDAQ:MNOV) has announced its support for an NIH-funded Expanded Access Protocol (EAP) trial to evaluate MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS). The NIH-NINDS has awarded $22 million for this intermediate-size trial, which will allow 200 ALS patients who are ineligible for the ongoing COMBAT-ALS trial to rec...
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
MediciNova, Inc. (NASDAQ:MNOV) has announced that an abstract regarding the COMBAT-ALS clinical trial of MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) treatment has been accepted for poster presentation at the 35th International Symposium on ALS / MND. The symposium will take place from Dec...
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
MediciNova (NASDAQ:MNOV) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering ibudilast to alleviate various post-COVID symptoms, including anxiety, fatigue, depre...
Medicinova Receives Notice of Allowance for New Patent Covering Mn-166 (Ibudilast) for the Prevention of Metastasis of Various Solid Cancer
No comment yet